CDSCO Draft Medical Devices (Amendment) Rules, 2026: Key Changes for Manufacturers

India’s medical device regulatory framework continues to evolve. The Ministry of Health & Family Welfare has released the Draft Medical Devices (Amendment) Rules, 2026, proposing amendments to the existing Medical Devices Rules, 2017.

The proposed changes aim to strengthen quality oversight while introducing clearer timelines for certain regulatory procedures. For medical device manufacturers operating in or targeting the Indian market, understanding these developments is important to anticipate potential impacts on licensing processes and Quality Management System (QMS) requirements.

What is changing under the Draft Medical Devices (Amendment) Rules, 2026?

One of the main proposed changes concerns the role of the Quality Management System audit in the manufacturing licence process.

Under the draft rules, a QMS audit conducted by a registered Notified Body would become mandatory before the grant of a manufacturing licence.

This proposed requirement reinforces the importance of demonstrating that an appropriate Quality Management System is effectively implemented before regulatory approval is granted.

The existing Medical Devices Rules, 2017 already include Quality Management System requirements for medical device manufacturers.

Clearer timelines for the regulatory process

The draft amendments also introduce more clearly defined timelines for different stages of the application and audit process.

These include timelines relating to:

• scrutiny of licence applications;

• completion of the QMS audit;

• submission and review of corrective actions following audit observations;

• completion of the verification process.

By defining these timelines more clearly, the proposed amendments are intended to make the regulatory process more predictable for manufacturers.

Potentially shorter manufacturing licence timelines

Another important element of the draft is the proposed reduction of certain approval timelines.

The objective is to improve licensing efficiency while maintaining the required level of regulatory and quality oversight.

For manufacturers, shorter and more clearly structured timelines could help improve planning when preparing applications for the Indian market.

However, this also places greater importance on submitting complete documentation and ensuring that the QMS is ready for assessment at the appropriate stage of the licensing process.

Increased attention to audit non-conformities

The proposed rules also emphasise the timely management and closure of non-conformities identified during QMS audits.

Manufacturers may therefore need to pay particular attention to their processes for:

• identifying audit findings;

• implementing corrective actions;

• documenting the actions taken;

• responding within the required regulatory timelines.

A well-prepared QMS and an effective corrective action process could therefore become even more important under the proposed regulatory framework.

What does this mean for medical device manufacturers?

If adopted, the amendments could contribute to greater regulatory predictability while reinforcing quality assurance requirements within the Indian medical device sector.

Companies manufacturing medical devices in India, or planning to enter the Indian market, should therefore consider reviewing their current regulatory strategy and QMS readiness.

In particular, manufacturers may wish to assess whether their documentation, internal processes and corrective action procedures are sufficiently prepared for a QMS audit conducted as part of the manufacturing licence process.

As these requirements are currently presented as draft amendments, companies should continue monitoring the regulatory process and prepare for the potential changes without treating the proposed provisions as final requirements.

Preparing for regulatory developments in India

The Draft Medical Devices (Amendment) Rules, 2026 demonstrate the continued evolution of India’s medical device regulatory framework, with increased emphasis on both regulatory efficiency and quality compliance.

Anticipating these developments can help manufacturers identify potential gaps early and adapt their regulatory strategy accordingly.

CEHTRA supports companies in navigating regulatory requirements across international markets, including the medical device sector. Our regulatory specialists can help organisations understand evolving requirements and assess their regulatory strategy in light of upcoming changes.

Need support with medical device regulatory requirements in India? Contact our experts to discuss your regulatory strategy.

Sources

• Central Drugs Standard Control Organization (CDSCO), Medical Devices Rules, 2017

• CDSCO / Ministry of Health & Family Welfare, Draft notification regarding amendments under Medical Devices Rules, 2017, G.S.R. 515(E), 23 June 2026

Contact our specialists